Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358278 | 0.81 | GAA (0.57) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL2030080 | 0.79 | GAA (0.55) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL3941087 | 0.79 | LMNA (0.50) | GAASMN1; SMN2ALDH1A1KDM4ETSHR | |
| SCHEMBL13366346 | 0.78 | GAA (0.55) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL748985 | 0.77 | GAA (0.58) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL4849683 | 0.77 | GAA (0.63) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL3397034 | 0.77 | HPGD (0.58) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL8162857 | 0.77 | GAA (0.53) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL15808582 | 0.77 | GAA (0.53) | GAASMN1; SMN2ALDH1A1KDM4EPKM | |
| SCHEMBL23683509 | 0.77 | GAA (0.49) | GAASMN1; SMN2ALDH1A1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | claimed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | GAA 4863/4885SMN1; SMN2 4526/4885ALDH1A1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.